FDA Reviewers Give Thumbs Down to New ALS Drug

TUESDAY, March 29, 2022 -- Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for amyotrophic lateral sclerosis (ALS).
In an analysis of Amylyx...

Source: Drugs.com - Pharma News - March 29, 2022 Category: Pharmaceuticals Source Type: news